With its eyes set on an IPO raise, InCarda unrolls mid-stage data backing inhaled arrhythmia drug

Max Gelman

Senior Editor

Working to craft an old arrythmia drug into a more user-friendly inhaled formulation, InCarda is expecting to use new Phase II data revealed Wednesday as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With its eyes set on an IPO raise, InCarda unrolls mid-stage data backing inhaled arrhythmia drug

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

With its eyes set on an IPO raise, In­Car­da un­rolls mid-stage da­ta back­ing in­haled ar­rhyth­mia drug

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

With its eyes set on an IPO raise, InCarda unrolls mid-stage data backing inhaled arrhythmia drug